CorMedix announces FDA acceptance of DefenCath NDA resubmission; PDUFA date Nov 15, 2023

CorMedix Inc.

FDA accepted DefenCath NDA resubmission as a complete Class 2 response with six-month review.
PDUFA target action date set for November 15, 2023.
DefenCath is a catheter lock solution to reduce bloodstream infections in hemodialysis patients.
CEO Joe Todisco highlighted preparations for potential commercial launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.